← Back to Search

Mobile Health Exercise for Cancer (GO-EXCAP2 Trial)

Led By Kah Poh Loh
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status of 0-3
Age ≥60 years (conventional definition of older age in clinical trials of MN)
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

GO-EXCAP2 Trial Summary

This trial is testing a new mobile health intervention to see if it's more effective than chemotherapy education in improving physical function and patient-reported outcomes in 100 older patients with MN.

Who is the study for?
This trial is for English-speaking older adults (60+) with Myeloid Neoplasms who are undergoing outpatient chemotherapy. They should be able to walk and have an ECOG status of 0-3, indicating varying levels of functional capacity. Those with conditions that prevent exercise or impair participation in the study cannot join.Check my eligibility
What is being tested?
The trial is testing a mobile health exercise app called GO-EXCAP against a control group receiving chemotherapy education. The goal is to see if the app improves physical function, mood, fatigue, and quality of life in patients compared to just getting educational support.See study design
What are the potential side effects?
Since this intervention involves exercise facilitated by an app rather than medication, side effects may include typical risks associated with physical activity such as muscle soreness or strain especially given the older population involved.

GO-EXCAP2 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I can care for myself but may not be able to do heavy physical work.
I am 60 years old or older.
I have been diagnosed with membranous nephropathy (MN).
I can walk 4 meters, with or without help from a device.

GO-EXCAP2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Difference between experimental and active comparator arms- Physical Function
Secondary outcome measures
Difference between experimental and active comparator arms -Depression
Difference between experimental and active comparator arms -Fatigue
Difference between experimental and active comparator arms -Quality of Life
Other outcome measures
Difference between experimental and active comparator arms -Inflammatory cytokines
Difference between experimental and active comparator arms- DNA methylation in the TNFα promoter region
Difference between experimental and active comparator arms- TNFα gene expression

GO-EXCAP2 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: GO-EXCAPExperimental Treatment1 Intervention
GO-EXCAP Mobile App involves the use of a mobile app delivery platform to deliver an exercise program [Exercise for Cancer Patients (EXCAP©®)]. EXCAP©®) is a progressive walking and resistance exercise program
Group II: Behavioral Placebo ControlActive Control1 Intervention
Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
First Studied
Drug Approval Stage
How many patients have taken this drug
GO-EXCAP Mobile App

Find a Location

Who is running the clinical trial?

University of RochesterLead Sponsor
836 Previous Clinical Trials
518,068 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,933,053 Total Patients Enrolled
7 Trials studying Myeloid Neoplasm
2,565 Patients Enrolled for Myeloid Neoplasm
Kah Poh LohPrincipal InvestigatorUniversity of Rochester
5 Previous Clinical Trials
210 Total Patients Enrolled

Media Library

GO-EXCAP Mobile App Clinical Trial Eligibility Overview. Trial Name: NCT04981821 — N/A
Myeloid Neoplasm Research Study Groups: Behavioral Placebo Control, GO-EXCAP
Myeloid Neoplasm Clinical Trial 2023: GO-EXCAP Mobile App Highlights & Side Effects. Trial Name: NCT04981821 — N/A
GO-EXCAP Mobile App 2023 Treatment Timeline for Medical Study. Trial Name: NCT04981821 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there currently an opportunity for patients to participate in this clinical trial?

"Clinicaltrials.gov has verified that this clinical trial is still enrolling participants, as the information was last updated on April 1st 2022; it had initially been posted three months prior to that."

Answered by AI

How many participants are being monitored as part of this research?

"Correct. Clinicaltrials.gov records show that this investigation has commenced recruiting, with a posting date of March 1st 2022 and an update on April 1st 2022. 100 individuals are being sought to participate at one location."

Answered by AI
~34 spots leftby Jun 2025